Durable remission after successful treatment of multidrug-resistant tuberculosis (MDRTB) among HIV-negative patients

E. E. Telzak, K. Sepkowitz, F. Medard, Peter L. Alpert, S. Blum, N. Salomon, G. Turett

Research output: Contribution to journalArticle

Abstract

We have previously described a 96% response rate to treatment among HIV-negative patients with MDRTB (resistance to at least isoniazid and rifampin). However, relapses may occur after treatment and initial median follow-up was only 22 months. Longer-term follow-up data for this cohort are now presented. All cases of MDRTB among confirmed HIV-negative persons at 7 New York City teaching hospitals were identified. Therapeutic response was evaluated by microbiologic and clinical criteria. Duration of follow-up was defined as the interval between the date appropriate therapy was initiated and the date of the last contact. Between 3/91 and 9/94, 25 patients were identified. Median age was 37 years and 14 (56%) were male. Fifteen (60%) patients were Black, 4 (16%) Hispanic, 4 Asian and 2 White. Seventeen (68%) had previously established risk factors for MDRTB, of whom 9 had known exposures to MDRTB including 8 health care workers. Twelve patients had isolates resistant to ≥ 4 first-line TB agents. Of the 25 patients, 22 (88%) responded to ≥ 3 drugs with in vitro activity against the isolate and remain free of disease (median of 44.5 months). One patient (4%) relapsed (after 17 months of treatment) and he responded to retreatment with 3 drugs with in vitro activity against the isolate. As previously reported, one patient died of overwhelming tuberculosis without receiving appropriate therapy and one resolved without treatment and remains in remission 71 months after diagnosis. With almost 4 years of follow-up, the relapse rate among HIV-negative persons with MDRTB is low. Patients can be expected to maintain durable remissions after responding successfully to appropriate treatment.

Original languageEnglish (US)
Pages (from-to)366
Number of pages1
JournalClinical Infectious Diseases
Volume25
Issue number2
StatePublished - 1997
Externally publishedYes

Fingerprint

Multidrug-Resistant Tuberculosis
HIV
Therapeutics
Recurrence
Retreatment
Urban Hospitals
Isoniazid
Rifampin
Hispanic Americans
Teaching Hospitals
Pharmaceutical Preparations
Tuberculosis
Delivery of Health Care

ASJC Scopus subject areas

  • Immunology

Cite this

Durable remission after successful treatment of multidrug-resistant tuberculosis (MDRTB) among HIV-negative patients. / Telzak, E. E.; Sepkowitz, K.; Medard, F.; Alpert, Peter L.; Blum, S.; Salomon, N.; Turett, G.

In: Clinical Infectious Diseases, Vol. 25, No. 2, 1997, p. 366.

Research output: Contribution to journalArticle

Telzak, EE, Sepkowitz, K, Medard, F, Alpert, PL, Blum, S, Salomon, N & Turett, G 1997, 'Durable remission after successful treatment of multidrug-resistant tuberculosis (MDRTB) among HIV-negative patients', Clinical Infectious Diseases, vol. 25, no. 2, pp. 366.
Telzak, E. E. ; Sepkowitz, K. ; Medard, F. ; Alpert, Peter L. ; Blum, S. ; Salomon, N. ; Turett, G. / Durable remission after successful treatment of multidrug-resistant tuberculosis (MDRTB) among HIV-negative patients. In: Clinical Infectious Diseases. 1997 ; Vol. 25, No. 2. pp. 366.
@article{eabd866afd504392bcbc948dab81ed95,
title = "Durable remission after successful treatment of multidrug-resistant tuberculosis (MDRTB) among HIV-negative patients",
abstract = "We have previously described a 96{\%} response rate to treatment among HIV-negative patients with MDRTB (resistance to at least isoniazid and rifampin). However, relapses may occur after treatment and initial median follow-up was only 22 months. Longer-term follow-up data for this cohort are now presented. All cases of MDRTB among confirmed HIV-negative persons at 7 New York City teaching hospitals were identified. Therapeutic response was evaluated by microbiologic and clinical criteria. Duration of follow-up was defined as the interval between the date appropriate therapy was initiated and the date of the last contact. Between 3/91 and 9/94, 25 patients were identified. Median age was 37 years and 14 (56{\%}) were male. Fifteen (60{\%}) patients were Black, 4 (16{\%}) Hispanic, 4 Asian and 2 White. Seventeen (68{\%}) had previously established risk factors for MDRTB, of whom 9 had known exposures to MDRTB including 8 health care workers. Twelve patients had isolates resistant to ≥ 4 first-line TB agents. Of the 25 patients, 22 (88{\%}) responded to ≥ 3 drugs with in vitro activity against the isolate and remain free of disease (median of 44.5 months). One patient (4{\%}) relapsed (after 17 months of treatment) and he responded to retreatment with 3 drugs with in vitro activity against the isolate. As previously reported, one patient died of overwhelming tuberculosis without receiving appropriate therapy and one resolved without treatment and remains in remission 71 months after diagnosis. With almost 4 years of follow-up, the relapse rate among HIV-negative persons with MDRTB is low. Patients can be expected to maintain durable remissions after responding successfully to appropriate treatment.",
author = "Telzak, {E. E.} and K. Sepkowitz and F. Medard and Alpert, {Peter L.} and S. Blum and N. Salomon and G. Turett",
year = "1997",
language = "English (US)",
volume = "25",
pages = "366",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Durable remission after successful treatment of multidrug-resistant tuberculosis (MDRTB) among HIV-negative patients

AU - Telzak, E. E.

AU - Sepkowitz, K.

AU - Medard, F.

AU - Alpert, Peter L.

AU - Blum, S.

AU - Salomon, N.

AU - Turett, G.

PY - 1997

Y1 - 1997

N2 - We have previously described a 96% response rate to treatment among HIV-negative patients with MDRTB (resistance to at least isoniazid and rifampin). However, relapses may occur after treatment and initial median follow-up was only 22 months. Longer-term follow-up data for this cohort are now presented. All cases of MDRTB among confirmed HIV-negative persons at 7 New York City teaching hospitals were identified. Therapeutic response was evaluated by microbiologic and clinical criteria. Duration of follow-up was defined as the interval between the date appropriate therapy was initiated and the date of the last contact. Between 3/91 and 9/94, 25 patients were identified. Median age was 37 years and 14 (56%) were male. Fifteen (60%) patients were Black, 4 (16%) Hispanic, 4 Asian and 2 White. Seventeen (68%) had previously established risk factors for MDRTB, of whom 9 had known exposures to MDRTB including 8 health care workers. Twelve patients had isolates resistant to ≥ 4 first-line TB agents. Of the 25 patients, 22 (88%) responded to ≥ 3 drugs with in vitro activity against the isolate and remain free of disease (median of 44.5 months). One patient (4%) relapsed (after 17 months of treatment) and he responded to retreatment with 3 drugs with in vitro activity against the isolate. As previously reported, one patient died of overwhelming tuberculosis without receiving appropriate therapy and one resolved without treatment and remains in remission 71 months after diagnosis. With almost 4 years of follow-up, the relapse rate among HIV-negative persons with MDRTB is low. Patients can be expected to maintain durable remissions after responding successfully to appropriate treatment.

AB - We have previously described a 96% response rate to treatment among HIV-negative patients with MDRTB (resistance to at least isoniazid and rifampin). However, relapses may occur after treatment and initial median follow-up was only 22 months. Longer-term follow-up data for this cohort are now presented. All cases of MDRTB among confirmed HIV-negative persons at 7 New York City teaching hospitals were identified. Therapeutic response was evaluated by microbiologic and clinical criteria. Duration of follow-up was defined as the interval between the date appropriate therapy was initiated and the date of the last contact. Between 3/91 and 9/94, 25 patients were identified. Median age was 37 years and 14 (56%) were male. Fifteen (60%) patients were Black, 4 (16%) Hispanic, 4 Asian and 2 White. Seventeen (68%) had previously established risk factors for MDRTB, of whom 9 had known exposures to MDRTB including 8 health care workers. Twelve patients had isolates resistant to ≥ 4 first-line TB agents. Of the 25 patients, 22 (88%) responded to ≥ 3 drugs with in vitro activity against the isolate and remain free of disease (median of 44.5 months). One patient (4%) relapsed (after 17 months of treatment) and he responded to retreatment with 3 drugs with in vitro activity against the isolate. As previously reported, one patient died of overwhelming tuberculosis without receiving appropriate therapy and one resolved without treatment and remains in remission 71 months after diagnosis. With almost 4 years of follow-up, the relapse rate among HIV-negative persons with MDRTB is low. Patients can be expected to maintain durable remissions after responding successfully to appropriate treatment.

UR - http://www.scopus.com/inward/record.url?scp=33748127119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748127119&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748127119

VL - 25

SP - 366

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 2

ER -